ETF Holdings Breakdown of LXRX

Stock Name	Lexicon Pharmaceuticals Inc
Ticker	LXRX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US5288723027

LXRX institutional holdings

The adjusted close for LXRX on 2025-11-11 was 1.56

The following institutional investment holdings of LXRX have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-11 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 242,712 USD 378,631 9.0% 1.56

2025-11-11 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 242,712 USD 378,631 9.0% 1.56

Total = 485,424 USD 757,262
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	242,712	USD 378,631 9.0%	1.56
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	242,712	USD 378,631 9.0%	1.56
Total =	485,424	USD 757,262

News associated with LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Average Rating of “Hold” by Analysts: Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) have earned a consensus rating of “Hold” from the five analysts that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price […] - 2025-07-10 05:48:56
HC Wainwright Reaffirms “Buy” Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX): Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $4.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 344.44% from the stock’s current price. […] - 2025-06-26 02:48:53
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving Average – Here’s What Happened: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.65 and traded as high as $0.75. Lexicon Pharmaceuticals shares last traded at $0.73, with a volume of 2,479,330 shares changing hands. Analyst Upgrades and Downgrades […] - 2025-06-24 05:14:58
Hennion & Walsh Asset Management Inc. Sells 33,201 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX): Hennion & Walsh Asset Management Inc. lessened its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 3.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 830,054 shares of the biopharmaceutical company’s stock after selling 33,201 shares […] - 2025-06-09 05:32:51
Deutsche Bank AG Boosts Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX): Deutsche Bank AG increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 378.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 315,659 shares of the biopharmaceutical company’s stock after acquiring an additional 249,616 shares during the quarter. Deutsche Bank AG’s holdings in Lexicon Pharmaceuticals were worth $234,000 as of […] - 2025-06-02 04:52:49
Woodline Partners LP Lowers Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX): Woodline Partners LP cut its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 81.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 229,376 shares of the biopharmaceutical company’s stock after selling 982,548 shares during the quarter. Woodline Partners […] - 2025-05-28 05:25:05
Contrasting Lexicon Pharmaceuticals (NASDAQ:LXRX) & Grifols (NASDAQ:GRFS): Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) and Grifols (NASDAQ:GRFS – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership. Profitability This table compares Lexicon Pharmaceuticals and Grifols’ net […] - 2025-05-26 02:20:56
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stake Boosted by Invesco Ltd.: Invesco Ltd. grew its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 60.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 104,494 shares of the biopharmaceutical company’s stock after purchasing an additional 39,420 shares during the quarter. Invesco Ltd.’s […] - 2025-05-06 04:28:46
Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com: StockNews.com initiated coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. A number of other analysts have also recently issued reports on the company. Needham & Company LLC reissued a “hold” […] - 2025-04-21 03:10:46
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus PT from Analysts: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) has been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective […] - 2025-04-04 02:12:45
Virtu Financial LLC Invests $66,000 in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX): Virtu Financial LLC purchased a new stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 88,982 shares of the biopharmaceutical company’s stock, valued at approximately $66,000. Other hedge funds and other […] - 2025-04-01 04:56:52
Swiss National Bank Grows Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX): Swiss National Bank increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 34.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 426,600 shares of the biopharmaceutical company’s stock after buying an additional 109,100 shares during the quarter. Swiss National Bank’s holdings in Lexicon Pharmaceuticals were worth $315,000 as of its […] - 2025-03-31 04:50:50
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of “Hold” from Analysts: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) has received a consensus rating of “Hold” from the five ratings firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price objective among brokerages […] - 2025-03-12 04:52:43
Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com: Equities research analysts at StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) in a report issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock. A number of other equities analysts have also recently issued reports on the company. Piper Sandler cut their target price on […] - 2025-03-12 04:19:02
Piper Sandler Issues Pessimistic Forecast for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price: Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) had its price objective lowered by Piper Sandler from $10.00 to $6.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. Several other brokerages have also issued reports on LXRX. Leerink Partners reissued a “market perform” rating […] - 2025-03-10 04:58:47
Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to Hold at Leerink Partnrs: Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) was downgraded by Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports. Other analysts have also recently issued reports about the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals […] - 2025-03-07 06:28:46

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.